HIGHLIGHTS OF PRESCRIBING INFORMATION
These highlights do not include all the information needed to use ELLENCE safely and effectively. See full prescribing information for ELLENCE.
ELLENCE® (epirubicin hydrochloride injection)
Initial U.S. Approval: 1999
WARNING: CARDIAC TOXICITY, SECONDARY MALIGNANCIES, EXTRAVASATION AND TISSUE NECROSIS, and SEVERE MYELOSUPPRESSION
If you provide additional keywords, you may be able to browse through our database of Scientific Response Documents.